NEW YORK (GenomeWeb) – Swiss bioinformatics company Saphetor announced today that it has signed multiple service agreements with University College London (UCL) for its precision medicine platform.
Saphetor's software-as-a-service platform automatically annotates and classifies genetic variants from next-generation sequencing data and is designed to help clinicians diagnose disease and select the most effective therapies.
Under the terms of the agreements, the company's platform will be used by UCL's Michel Michaelides, who studies eye disorders, and Vincent Plagnol, who leads the UCL Exome Consortium for rare disease research.
Additional terms of the deals were not disclosed.
In September, Saphetor signed on to provide NGS analysis services to Geneva University Hospitals.